Cervical screening in HPV-vaccinated populations

Area of Science:

• Oncology
• Public Health
• Infectious Diseases

Background:

• Cervical screening with cytology has significantly reduced cervical cancer rates.
• Recent advancements include human papillomavirus (HPV) DNA testing and widespread HPV vaccination.

Purpose of the Study:

• To review the evolution of cervical screening strategies.
• To discuss the integration of HPV testing and vaccination into screening programs.
• To explore optimization of HPV screening benefits in diverse populations.

Main Methods:

• Review of current evidence on HPV DNA testing sensitivity compared to cytology.
• Analysis of strategies to improve HPV test specificity for precancerous lesions.
• Examination of age recommendations and screening intervals for HPV screening.
• Discussion of clinical HPV test development and triage methods for HPV-positive individuals.

Main Results:

• HPV DNA testing demonstrates higher sensitivity than cytology for detecting precancerous cervical lesions.
• Optimized screening protocols involve age-specific recommendations (25-30 years) and intervals.
• Clinical HPV tests with reduced sensitivity for low viral loads and effective triage systems enhance specificity.
• These advancements aim to maximize the benefits of HPV screening in both vaccinated and unvaccinated populations.

Conclusions:

• HPV DNA testing is a more sensitive tool for cervical cancer screening.
• Adjusting screening age, refining HPV tests, and implementing triage strategies are crucial for effective HPV screening.
• Optimized HPV screening protocols enhance early detection and prevention of cervical cancer across different population groups.